(Q45399692)

English

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

scientific article published on 29 September 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). (English)

1 reference

Europe PubMed Central

14 December 2017

Simian immunodeficiency virus

0 references

1 reference

based on heuristic

inferred from title

Marjorie Robert-Guroff

13

object named as

Marjorie Robert-Guroff

1 reference

Europe PubMed Central

14 December 2017

author name string

Qifeng Zhou

1

1 reference

Europe PubMed Central

14 December 2017

Rachmat Hidajat

2

1 reference

Europe PubMed Central

14 December 2017

Bo Peng

3

1 reference

Europe PubMed Central

14 December 2017

David Venzon

4

1 reference

Europe PubMed Central

14 December 2017

M Kristine Aldrich

5

1 reference

Europe PubMed Central

14 December 2017

Ersell Richardson

6

1 reference

Europe PubMed Central

14 December 2017

Eun Mi Lee

7

1 reference

Europe PubMed Central

14 December 2017

V S Kalyanaraman

8

1 reference

Europe PubMed Central

14 December 2017

George Grimes

9

1 reference

Europe PubMed Central

14 December 2017

V Raúl Gómez-Román

10

1 reference

Europe PubMed Central

14 December 2017

L Ebonita Summers

11

1 reference

Europe PubMed Central

14 December 2017

Nina Malkevich

12

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

29 September 2007

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

25

1 reference

Europe PubMed Central

14 December 2017

47

1 reference

Europe PubMed Central

14 December 2017

8021-8035

1 reference

Europe PubMed Central

14 December 2017

Immunologic correlates of protection induced by vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Progress in the development of an HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Development of formulations that enhance physical stability of viral vectors for gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Development and homeostasis of T cell memory in rhesus macaque

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Protective immunity towards intracellular pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Central memory and effector memory T cell subsets: function, generation, and maintenance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Lymphocyte homing and homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Mucosal vaccines: the promise and the challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in M

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Intranasal delivery of vaccines against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Adenovirus vaccines in the U.S. military

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

based on heuristic

inferred from DOI database lookup

An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.017

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.09.017

1 reference

Europe PubMed Central

14 December 2017

release_omelewucizb5pfjdejtlwui2bi

1 reference

https://api.fatcat.wiki/v0/release/omelewucizb5pfjdejtlwui2bi

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45399692&oldid=1844493299"